193 related articles for article (PubMed ID: 29141850)
21. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
Young Han C; Bedia JS; Yang WL; Hawley SJ; Bergan L; Hopper M; Celestino J; Guo J; Gornet TG; Soosaipillai A; Yang H; Doskocil SD; Lokshin AE; Handy BC; Diamandis EP; Moore RG; Lu KH; Lu Z; Anderson KS; Drescher CW; Skates SJ; Bast RC
Br J Cancer; 2024 Mar; 130(5):861-868. PubMed ID: 38195887
[TBL] [Abstract][Full Text] [Related]
22. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
[TBL] [Abstract][Full Text] [Related]
23. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
[TBL] [Abstract][Full Text] [Related]
25. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
27. Mapping Epitopes Recognised by Autoantibodies Shows Potential for the Diagnosis of High-Grade Serous Ovarian Cancer and Monitoring Response to Therapy for This Malignancy.
Moody R; Wilson K; Kampan NC; McNally OM; Jobling TW; Jaworowski A; Stephens AN; Plebanski M
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439354
[TBL] [Abstract][Full Text] [Related]
28. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
29. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
30. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
[TBL] [Abstract][Full Text] [Related]
31. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
32. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer.
Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X
Front Immunol; 2021; 12():698312. PubMed ID: 34489945
[TBL] [Abstract][Full Text] [Related]
33. Characterization of serum biomarkers for detection of early stage ovarian cancer.
Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
[TBL] [Abstract][Full Text] [Related]
34. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
35. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
Taylor DD; Gercel-Taylor C; Parker LP
Gynecol Oncol; 2009 Oct; 115(1):112-120. PubMed ID: 19647308
[TBL] [Abstract][Full Text] [Related]
36. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
[TBL] [Abstract][Full Text] [Related]
37. Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence.
Chatterjee M; Dyson G; Levin NK; Shah JP; Morris R; Munkarah A; Tainsky MA
Cancer Biomark; 2012; 11(2-3):59-73. PubMed ID: 23011153
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
Fan HY; Duan DM; Liu YF
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
[TBL] [Abstract][Full Text] [Related]
39. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
40. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
